Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2025

Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis

Arthritis Rheumatol 2025;77:536–46 doi: 10.1111/1756-185X.70212

Paley M,

Wung P,

Poddubnyy et al. identified no apparent increase in the risk of developing extramusculoskeletal manifestations (EMMs) in patients with PsA, r-axSpA, and nr-axSpA receiving 15mg UPA in the SELECT trials. Majority of patients did not report a history of EMMs at baseline, regardless of disease indication or study treatment.

Keywords:

January 2025

Development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis

Arthritis & Rheumatology 2024. Epub ahead of print doi: 10.1002/art.43069

Paley M,

Wung P,

Poddubnyy et al. analysed five clinical trials to evaluate extra-musculoskeletal manifestations (EMMs) like uveitis, IBD, and psoriasis in patients treated with UPA. They observed low incidences across PsA, r-axSpA, and nr-axSpA. Numerically, uveitis rates were lower in
UPA-treated patients than in those receiving placebo, particularly in r-axSpA.

Keywords:

Updacitinib

October 2024

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

MD Open. 2024 Sep 20;10:e004318 doi: 10.1136/rmdopen-2024-004318

Ng KJ,

Morel J,

Alten R,

Zhu B,

Kristensen et al. compared 14 PsA drugs across five treatment classes, evaluating their real-world effectiveness over three months. Ixekizumab showed rapid effectiveness on joint disease activity and skin outcomes, performing better than IL-12/23i and IL-23i, and comparable to TNFi and JAKi. More patients with active psoriasis achieved minimal disease activity with Ixekizumab than other therapies.